**From:** XXXX XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXX

**Sent:** 28 January 2021 09:51

**To:** XXXXX XXXXX

**Cc:** XXXXX XXXXX; XXXXX XXXXXX; XXXXXX X XXXXXXXX; XXXXXXXX XXXX; XXXXXX XXXXXXXX

**Subject:** RE: Initial scrutiny letter: Heart failure (reduced ejection fraction) - dapagliflozin [ID1656]

Dear XXXXX,

The Board recognise the limitations of the appraisal process and do not want to appeal the overall decision, rather objecting to the wording that sacubitril valsartan should be considered a comparator.

As this is lodged we have no further comment and will make sure BSH external communications clarify the practical aspects of clinical practice.

Many thanks,

XXXX.

XXXX XXXXXXXXXXXX

British Society for Heart Failure

33 Cavendish Square

London

W1G 0PW



Phone: 0203 606 0794

Website: [www.bsh.org.uk](http://www.bsh.org.uk/)  
Twitter: @BSHeartFailure  
Company No: 3767312  
Registered charity number: 1075720

[MAKE **HEART FAILURE** A NATIONAL PRIORITY](https://www.bsh.org.uk/about/what-we-do/)